bristol-myers-squibb-company-and-otsuka-pharmaceutical-europe-ltd

Médias

Three-Year Follow-Up Data for SPRYCEL®▼ (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase